cme

Home/Tag: cme

SLRA 2019 EULAR Conference

June 26, 2019 @ 6:00 pm 9:00 pm

St. Louis Rheumatology Association

Wednesday, June 26, 2019

2019 EULAR Conference: Update on Clinical and Lab Research findings for RA, PSA, Lupus

 

Vibeke Strand, M.D.

Presenter: Vibeke Strand, M.D. Adjunct Clinical Professor of Medicine Division of Immunology/Rheumatology, Stanford University

Vibeke Strand, MD, FACP, FACR is theAdjunct Clinical Professor for the Division of Immunology/Rheumatology at  Stanford University and a Biopharmaceutical Consultant

 

 

6:15 – 7:00 pm Registration

7:00 – 9:00 pm Presentation and dinner

Preston Restaurant (Chase Park Plaza)
212 Kingshighway Blvd, St Louis, MO 63108

Preston Restaurant

212 Kingshighway Blvd
St. Louis, 63108 United States
Google Map
(314) 633-7800
https://www.theprestonstl.com/

This live activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Washington University School of Medicine, Continuing Medical Education and St. Louis Rheumatology Association.  Washington University is accredited by the ACCME to provide continuing medical education for physicians.  Washington University designates this live activity for a maximum of _1_ AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

It is the policy of Washington University School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational activities.  All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations.  Any potential conflicts were addressed and resolved.  All members of the CME department have nothing to disclose.  Speakers are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.

Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients.  All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis. These presentations are not an endorsement of any commercial interests. These presentations are the views and experiences of the presenters.  The presenters’ views do not represent the policy or position of Washington University School of Medicine.  Washington University School of Medicine, Continuing Medical Education, is the sponsor for CME credits.

St. Louis Rheumatology Association

http://internalmed.slu.edu/

Opioids and the Workplace CME

Mizzou // University of Missouri

Mizzou // University of Missouri

January 10 – 11, 2019

There is a compelling need to change how we look at the opioid problem, specifically its impact on workers and the workforce.

This two-day event will kick off a series of programs around Missouri designed to bring together people who make policy, people who influence policy, and those affected by these policies.

The goal is to develop a realistic action plan, developed by and for the people most involved with the problem.

We invite you to be a part of the discussion, and to help initiate real change in Missouri.

Target Audience:

  • Business leaders who are in position to influence how their business’ employment practices are set.
  • Labor leaders who recruit, train and maintain a large force of ready-trained workers, particularly from organizations that also provide health insurance plans.
  • Health Care professionals interested in looking for alternative treatments and ways to reduce OUD.
  • Community members, those who work directly in the field with OUD sufferers as well as family members of sufferers and others who want to know more about what can be done differently than is being done now.

Objectives/Outcomes

  • Understand how opioids are impacting the workforce
  • Understand how and why the current employment practices dealing with opioids are problematic and likely to get worse
  • Explore new ideas and ways of dealing with pain management, medication, perspectives of Opioid Use Disorder (OUD) recovery, as well as return to work policies.
  • Develop changes that could be made concerning employment and the intersection of consequences of the opioid crisis.
  • Learn current information on the opioid crisis
  • Discuss the crisis as well as solutions with individuals from different backgrounds

Topics Include:

  • Defining the opioid use crisis and its impact on the workforce
  • The economic impact of addiction on individuals, businesses and the community
  • Examining what does and doesn’t work in dealing with the crisis
  • Building collaborations
  • Creating realistic strategies

Activity approved for AMA PRA Category 1 Credit(s)™

The University of Missouri Sinclair School of Nursing is an approved provider of continuing education by the Midwest Multistate Division, an accredited approver by the American Nurses’ Credentialing Center’s Commission on Accreditation.

Midwest Multistate Division Provider Number MO 1019-7

The Missouri Bar has approved this program for 11.4 hours of CLE credit.

Pharmacy: The Continuing Education Committee of the Board of Pharmacy has reviewed and approved the conference for 1 CE(s) per session. Program number: 2018-11-11

Presented by: Labor Studies Program, UMSL | University of Missouri ExtensionMU Sinclair School of Nursing | MU Center for Continuing Medical Education & Physician Lifelong Learning

Conference information will be added as it becomes available.

16th Annual Galaxy of Gastroenterology

Washington University School of Medicine

Washington University School of Medicine

November 2 & 3, 2018

Who Should Attend?

This seminar is designed for primary care physicians, gastroenterologists, gastrointestinal surgeons and their associates who participate in the care of patients with gastrointestinal and hepatic disorders.

The course will also be of value to technicians, nurses and physicians who participate in endoscopy, gastrointestinal motility procedures, and pH-monitoring procedures.

Parts of this activity may also be of benefit to pulmonologists and ear, nose, throat specialists.

Course Director

Gregory S. Sayuk, MD, MPH

Learning & Performance Objectives

The intended result of this continuing medical education activity is to improve knowledge, competence, performance and patient outcomes in the management of gastroenterological diseases by primary care physicians, gastroenterologists, and ancillary staff involvement in the management of gastroenterological diseases.  At the completion of this seminar the participant should be able to:

  • Review clinical presentation and work-up of common GI ailments, including anorectal disorders, IBS, and celiac disease.
  • Explain diagnostic and therapeutic algorithms relevant to GI disorders.
  • Comprehend the mechanistic basis for management of commonly encountered GI ailments.
  • Become aware of the newest techniques, procedures and therapies in gastroenterology, including endo-FLIP.
  • Discuss the evaluation and monitoring of management of inflammatory bowel diseases (IBD).
  • Discuss new paradigms in the medical management of liver disease, including hepatitis C.
  • Discuss the management options available for obscure GI bleeding.
  • Analyze new investigative and therapeutic options in the management of gastroparesis and gastroesophageal reflux.
  • Recognize the use of pharmacologic management in functional GI disorders.
  • Review current approaches to diagnosis and management of alcoholic and non-alcoholic fatty liver.
  • Recognize the options for colon cancer screening and the clinical factors associated with hereditary GI cancer syndromes.

Accreditation

In support of improving patient care, Washington University School of Medicine in St. Louis is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit available for this activity:

American Medical Association (AMA): Washington University School of Medicine in St. Louis designates this live activity for a maximum of 11.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Nurses Credentialing Center (ANCC): Washington University School of Medicine in St. Louis designates this live activity for a maximum of 11 ANCC contact hours.

Accreditation Council for Pharmacy Education (ACPE) This activity is approved for contact hours 11.5 (1.15 CEUs). Attending the full program will earn contact hours 11.5(1.15 CEUs). JA0000340-0000-19-004-L01-P Unique Universal Activity Number. To be awarded credit, participants must have participated in all sessions for the day credit is claimed and complete activity evaluation

ABIM MOC Points: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.5 MOC points in Medical Knowledge in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

SLRA Presentation & Dinner – September 2018

St. Louis University School of Medicine

St. Louis Rheumatology Association

Thursday, September 20th, 2018

Drug Pricing; How did we get here and where are we going?

Presenter: Steve Miller, MD, MBA, Senior Vice President & Chief Medical Officer, Express Scripts

Steve Miller, MD, MBASteve Miller has served as Chief Medical Officer at Express Scripts since 2006, focusing on supporting government relations, leading the Pharmacy & Therapeutics committee, managing the Medical Affairs team and interfacing with client groups.

He received his medical degree from the University of Missouri-Kansas City, and he trained in the Pathology and Research fellowship at the University of Alabama at Birmingham.

He degrees in Internal Medicine which he recieved at the University of Colorado, Nephrology at Washington University, and did a cardiology research fellowship at University of California-San Francisco. Miller earned his MBA at Olin.

Dr. Steve Miller’s expertise represents years as a  medical researcher, clinician and administrator, and spans numerous healthcare  subjects. Since joining the company in 2005, Dr. Miller has represented Express Scripts as a presenter at nationwide conferences.

At Express Scripts, he is actively involved in developing their clinical programs and advancing the use of generic pharmaceuticals and  specialty medications. Dr. Miller is a leader in the promotion of legislation to create a pathway at the U.S. Food and Drug Administration for the regulation of biogenerics and biosimilars.

Prior to joining Express Scripts, Dr. Miller was the vice president and chief  medical officer at Barnes-Jewish Hospital, Washington University School of  Medicine in St. Louis.

6:15 – 7:00 pm Registration

7:00 – 9:00 pm Presentation and dinner

Herbie’s

This live activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Washington University School of Medicine, Continuing Medical Education and St. Louis Rheumatology Association.  Washington University is accredited by the ACCME to provide continuing medical education for physicians.  Washington University designates this live activity for a maximum of _1_ AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

It is the policy of Washington University School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational activities.  All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations.  Any potential conflicts were addressed and resolved.  All members of the CME department have nothing to disclose.  Speakers are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations.

Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients.  All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis. These presentations are not an endorsement of any commercial interests. These presentations are the views and experiences of the presenters.  The presenters’ views do not represent the policy or position of Washington University School of Medicine.  Washington University School of Medicine, Continuing Medical Education, is the sponsor for CME credits.

SLRA Presentation & Dinner – March 2018

Saint Louis University School of Medicine

St. Louis Rheumatology Association

Wednesday, March 21, 2018

Jeffrey A. Sparks, MD, MMSc

CME: Update on the Studies to Evaluate the Etiology and Public Health Burden of Rheumatic Diseases

Jeffrey A. Sparks, MD, MMSc -Division of Rheumatology/Immunology & Assistant Professor of Medicine at Harvard Medical School.

Dr. Sparks is a rheumatologist and population scientist with an overall focus on using patient-oriented and epidemiologic research studies to evaluate the etiology, outcomes, and public health burden of rheumatic diseases such as rheumatoid arthritis (RA). In particular, he performs studies to evaluate the genetic, environmental, serologic, and familial risk factors for RA, clinical trials for RA prevention, RA outcomes research focusing on the respiratory burden of RA, evaluates metabolic factors such as weight loss for RA outcomes, and investigates rheumatic manifestations of osseous sarcoidosis.

6:30 – 7:30 pm Registration

7:30 – 9:00 pm Presentation and dinner

Nieman Marcus, Zodiac Room, Hwy 40 and

Lindbergh

REGISTER FOR CME

This live activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Washington University School of Medicine, Continuing Medical Education and St. Louis Rheumatology Association.  Washington University is accredited by the ACCME to provide continuing medical education for physicians.  Washington University designates this live activity for a maximum of _1_ AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

It is the policy of Washington University School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational activities.  All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations.  Any potential conflicts were addressed and resolved.

 All members of the CME department have nothing to disclose.  Speakers are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations. Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients.  All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis.

These presentations are not an endorsement of any commercial interests. These presentations are the views and experiences of the presenters.  The presenters’ views do not represent the policy or position of Washington University School of Medicine.  Washington University School of Medicine, Continuing Medical Education, is the sponsor for CME credits.

SLRA Presentation & Dinner – February 2018

Saint Louis University School of Medicine

St. Louis Rheumatology Association

Wednesday, February 21, 2018

Richard Brasington, M.D., F.A.C.P.

Update on Clinical Research and Treatment of Inflammatory Arthritis

Richard Brasington, M.D., F.A.C.P.
Professor of Medicine
Division of Immunology/Rheumatology
Washington University School of Medicine

6:30– 7:30 pm Registration

7:30 – 9:00 pm Presentation and dinner

The New Herbie’s
8100 Maryland Avenue in Clayton
314-769- 9595

REGISTER FOR CME

This live activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Washington University School of Medicine, Continuing Medical Education and St. Louis Rheumatology Association.  Washington University is accredited by the ACCME to provide continuing medical education for physicians.  Washington University designates this live activity for a maximum of _1_ AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

It is the policy of Washington University School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational activities.  All planners, faculty and other persons who may influence content of this CME activity have disclosed all relevant financial relationships with commercial interests. All disclosures have been reported and are indicated with their presentations.  Any potential conflicts were addressed and resolved.

 All members of the CME department have nothing to disclose.  Speakers are also expected to openly disclose inclusion of discussion of any off-label, experimental, or investigational use of drugs or devices in their presentations. Presentations are expected to be based on evidence that is accepted within the profession of medicine as adequate justification for their indication in the care of patients.  All scientific research should conform to the generally accepted standards of experimental design, data collection and analysis.

These presentations are not an endorsement of any commercial interests. These presentations are the views and experiences of the presenters.  The presenters’ views do not represent the policy or position of Washington University School of Medicine.  Washington University School of Medicine, Continuing Medical Education, is the sponsor for CME credits.

Proposed Rule Would End Sunshine Act’s CME Exclusion

The CMS intends to eliminate the exclusion for continuing medical education in the Open Payments program, more commonly known as the Sunshine Act, which requires drug and device companies to disclose payments to physicians.

The reversal was included in the proposed Physician Fee Schedule for 2015, which also would make changes that would benefit primary-care medicine at the expense of payments to specialties.

The regulations also include a variety of changes to the Shared Savings Program service for accountable care organizations, the Physician Quality Reporting System and the incentive program for electronic health records. And it would expand the array of telehealth services that qualify for Medicare reimbursement.

The Open Payments Program

Sponsorships for CME were initially given a pass in the Open Payments program because the CMS believed adequate safeguards were already in place. Many experts, however, argued that the exclusion would allow drug and device companies to avoid disclosure by shifting marketing dollars to CME from direct promotional programs.

In the proposed rule, the CMS said “an unintended consequence” of the policy was the appearance the agency was tacitly endorsing corporate sponsorships of continuing education events. The Open Payments program stems from a provision of the Patient Protection and Affordable Care Act known as the Sunshine Act.

CME organizations and manufacturers that fund education events were blindsided by the move, said Andrew Rosenberg, senior adviser for the CME Coalition, a trade group.

“If it is allowed to stand, this policy change will be massively disruptive to every stakeholder in the CME ecosystem—doctors, educators and commercial supporters—who have spent over a year preparing for the implementation of the current rules,” Rosenberg wrote in an e-mail to Modern Healthcare late Friday. Extending the disclosure to CME, he added, would “discourage physicians from learning new medical science by creating a false stigma.”

Meanwhile, the rule’s suggested changes in the “relative value units” that determine Medicare payments to physicians must be revenue-neutral, so increases in payments in one area lead to cuts elsewhere.

Reclassification of Codes

The CMS proposed cutting Medicare payments for radiation therapy centers and radiation oncology services by 8% and 4% respectively by reclassifying equipment purchases as indirect expenses of providing care.

At the same time, the rule would increase payments for family practice (2%), internal medicine (2%) and geriatrics (1%), due to changes stemming from the CMS previously undervaluing the work required in those specialties, the proposal says. In addition, independent laboratories would get a 3% bump based on increases in the cost of running such an organization.

“Consistent with amendments to the Affordable Care Act, CMS has been engaged in a vigorous effort over the past several years to identify and review potentially misvalued codes, and to make adjustments where appropriate,” CMS officials said in a statement. “We identified most of these by reviewing high-expenditure services by specialty that have not been recently reviewed. Several other proposed services were identified in a variety of ways, including through our public nomination process.”